Suppr超能文献

肠道微生物群与肝脏疾病的并发症

Gut Microbiota and Complications of Liver Disease.

作者信息

Acharya Chathur, Bajaj Jasmohan S

机构信息

Division of General Internal Medicine, Virginia Commonwealth University, 1200 E Broad St, Richmond, VA 23298, USA.

Division of Gastroenterology, Hepatology, and Nutrition, McGuire VA Medical Center, Virginia Commonwealth University, 1201 Broad Rock Boulevard, Richmond, VA 23249, USA.

出版信息

Gastroenterol Clin North Am. 2017 Mar;46(1):155-169. doi: 10.1016/j.gtc.2016.09.013.

Abstract

Chronic liver disease, cirrhosis, and its complications are epidemic worldwide. Most complications are mediated through a dysfunctional gut-liver axis. New techniques have made culture-independent analysis of the gut microbiome widespread. With insight into an unfavorable microbiome (dysbiosis) and how it affects liver disease, investigators have discovered new targets to potentially improve outcomes. Dysbiosis is associated with endotoxemia and propagates liver injury due to nonalcoholic steatohepatitis and alcohol. The composition and functionality of the microbiome changes with the development of cirrhosis, decompensation, and with treatments for these conditions. Gut microbiota can be used to predict clinically relevant outcomes in cirrhosis.

摘要

慢性肝病、肝硬化及其并发症在全球范围内流行。大多数并发症是通过功能失调的肠-肝轴介导的。新技术使对肠道微生物群的非培养分析广泛应用。随着对不良微生物群(生态失调)及其如何影响肝病的深入了解,研究人员发现了可能改善预后的新靶点。生态失调与内毒素血症有关,并因非酒精性脂肪性肝炎和酒精而加重肝损伤。微生物群的组成和功能随着肝硬化、失代偿的发展以及针对这些病症的治疗而发生变化。肠道微生物群可用于预测肝硬化的临床相关预后。

相似文献

1
Gut Microbiota and Complications of Liver Disease.
Gastroenterol Clin North Am. 2017 Mar;46(1):155-169. doi: 10.1016/j.gtc.2016.09.013.
2
Alcoholic liver disease: the gut microbiome and liver cross talk.
Alcohol Clin Exp Res. 2015 May;39(5):763-75. doi: 10.1111/acer.12704.
3
Nonalcoholic Fatty Liver Disease and the Gut Microbiome.
Clin Liver Dis. 2016 May;20(2):263-75. doi: 10.1016/j.cld.2015.10.012. Epub 2015 Dec 24.
4
Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
Aliment Pharmacol Ther. 2018 Jan;47(2):192-202. doi: 10.1111/apt.14397. Epub 2017 Oct 30.
5
Alcohol, liver disease and the gut microbiota.
Nat Rev Gastroenterol Hepatol. 2019 Apr;16(4):235-246. doi: 10.1038/s41575-018-0099-1.
6
Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis.
Eur J Nutr. 2018 Apr;57(3):861-876. doi: 10.1007/s00394-017-1524-x. Epub 2017 Sep 5.
7
The gut-liver axis in liver disease: Pathophysiological basis for therapy.
J Hepatol. 2020 Mar;72(3):558-577. doi: 10.1016/j.jhep.2019.10.003. Epub 2019 Oct 14.
8
Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
Hepatol Int. 2018 Feb;12(Suppl 1):24-33. doi: 10.1007/s12072-017-9798-x. Epub 2017 May 26.
9
Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis.
Ann Hepatol. 2019 Nov-Dec;18(6):796-803. doi: 10.1016/j.aohep.2019.06.020. Epub 2019 Sep 13.
10
[Gut microbiota and nonalcoholic steatohepatitis].
Nihon Yakurigaku Zasshi. 2018;152(4):187-193. doi: 10.1254/fpj.152.187.

引用本文的文献

1
Microbial Approaches to Treat and Prevent Hepatic Encephalopathy.
Gastroenterol Clin North Am. 2025 Jun;54(2):429-451. doi: 10.1016/j.gtc.2024.12.006. Epub 2025 Jan 23.
2
Gut‑liver axis in liver disease: From basic science to clinical treatment (Review).
Mol Med Rep. 2025 Jan;31(1). doi: 10.3892/mmr.2024.13375. Epub 2024 Oct 25.
4
The signatures and crosstalk of gut microbiome, mycobiome, and metabolites in decompensated cirrhotic patients.
Front Microbiol. 2024 Aug 21;15:1443182. doi: 10.3389/fmicb.2024.1443182. eCollection 2024.
5
Effects of N1115 on gut microbial imbalance and liver function in patients with hepatitis B-related cirrhosis.
World J Gastroenterol. 2024 Mar 21;30(11):1556-1571. doi: 10.3748/wjg.v30.i11.1556.
7
An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations.
Hepatology. 2023 Dec 1;78(6):1843-1857. doi: 10.1097/HEP.0000000000000474. Epub 2023 May 25.
8
Therapeutic possibilities of gut microbiota modulation in acute decompensation of liver cirrhosis.
World J Hepatol. 2023 Apr 27;15(4):525-537. doi: 10.4254/wjh.v15.i4.525.
9
Comparison of intestinal flora between patients with chronic and advanced Schistosoma japonicum infection.
Parasit Vectors. 2022 Nov 7;15(1):413. doi: 10.1186/s13071-022-05539-6.
10
Potential Gut Microbiota Features for Non-Invasive Detection of Schistosomiasis.
Front Immunol. 2022 Jul 14;13:941530. doi: 10.3389/fimmu.2022.941530. eCollection 2022.

本文引用的文献

1
The role of Gut Microbiota in the development of obesity and Diabetes.
Lipids Health Dis. 2016 Jun 18;15:108. doi: 10.1186/s12944-016-0278-4.
2
Impaired Gut-Liver-Brain Axis in Patients with Cirrhosis.
Sci Rep. 2016 May 26;6:26800. doi: 10.1038/srep26800.
3
Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease.
PLoS One. 2016 May 20;11(5):e0151829. doi: 10.1371/journal.pone.0151829. eCollection 2016.
6
Decompensated cirrhosis and microbiome interpretation.
Nature. 2015 Sep 17;525(7569):E1-2. doi: 10.1038/nature14851.
7
Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis.
Dig Dis Sci. 2015 Nov;60(11):3318-28. doi: 10.1007/s10620-015-3776-8. Epub 2015 Jul 3.
8
Alcoholic liver disease: the gut microbiome and liver cross talk.
Alcohol Clin Exp Res. 2015 May;39(5):763-75. doi: 10.1111/acer.12704.
9
Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy.
Hepatology. 2015 Oct;62(4):1260-71. doi: 10.1002/hep.27819. Epub 2015 May 6.
10
Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality.
J Gastroenterol Hepatol. 2015 Sep;30(9):1429-37. doi: 10.1111/jgh.12932.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验